These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 35509211)

  • 1. Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer.
    Chen J; Liao Y; Li R; Luo M; Wu G; Tan R; Xiao Z
    Technol Cancer Res Treat; 2022; 21():15330338221090093. PubMed ID: 35509211
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma.
    Xu Q; Xu H; Deng R; Li N; Mu R; Qi Z; Shen Y; Wang Z; Wen J; Zhao J; Weng D; Huang W
    Cancer Cell Int; 2021 Apr; 21(1):190. PubMed ID: 33794886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
    Lai J; Yang H; Xu T
    BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological Characteristics of Alternative Splicing Profiles Related to Prognosis in Bladder Cancer.
    Ye F; Liang Y; Cheng Z; Liu Y; Hu J; Li W; Chen X; Gao J; Jiang H
    Front Immunol; 2022; 13():911902. PubMed ID: 35769470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of a signature based on myofibroblastic cancer-associated fibroblast marker genes for predicting prognosis, immune infiltration, and therapeutic response in bladder cancer.
    Qin R; Ma X; Pu S; Shen C; Hu D; Liu C; Wang K; Wang Y
    Investig Clin Urol; 2024 May; 65(3):263-278. PubMed ID: 38714517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of RNA Modification-Associated Alternative Splicing Signature as an Independent Factor in Head and Neck Squamous Cell Carcinoma.
    Liu J; Deng W; Xiao Z; Huang X; Lin M; Long Z
    J Immunol Res; 2022; 2022():8976179. PubMed ID: 36157883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
    Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H
    Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clear cell renal cell carcinoma: immunological significance of alternative splicing signatures.
    Zhang J; Jiang H; Rao D; Jin X
    Front Oncol; 2023; 13():1206882. PubMed ID: 38288096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
    Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
    J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
    Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
    Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
    Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
    Front Genet; 2022; 13():872186. PubMed ID: 35937991
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
    Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H
    Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures.
    Dong Y; Wu X; Xu C; Hameed Y; Abdel-Maksoud MA; Almanaa TN; Kotob MH; Al-Qahtani WH; Mahmoud AM; Cho WC; Li C
    Aging (Albany NY); 2024 Feb; 16(3):2591-2616. PubMed ID: 38305808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-Wide Profiling of Alternative Splicing Signatures Associated with Prognosis and Immune Microenvironment of Hepatocellular Carcinoma.
    Liu Z; Ye J; Khan AA; Chen J; Zhou L; Zheng S; Xu X
    Med Sci Monit; 2021 Aug; 27():e930052. PubMed ID: 34407065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative splicing events in tumor immune infiltration in renal clear cell carcinomas.
    Wang Z; Zhu L; Li K; Sun Y; Giamas G; Stebbing J; Peng L; Yu Z
    Cancer Gene Ther; 2022 Oct; 29(10):1418-1428. PubMed ID: 35370291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and validation of a prognostic model for bladder cancer based on disulfidptosis-related lncRNAs.
    Yang X; Zhang Y; Liu J; Feng Y
    Medicine (Baltimore); 2024 Jul; 103(27):e38750. PubMed ID: 38968515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
    Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
    Front Immunol; 2022; 13():916800. PubMed ID: 35860239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.
    Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G
    BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A transient receptor potential channel-related model based on machine learning for evaluating tumor microenvironment and immunotherapeutic strategies in acute myeloid leukemia.
    Hua J; Ding T; Shao Y
    Front Immunol; 2022; 13():1040661. PubMed ID: 36591215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.